tbuckley/cabot-search huggingface dataset:
Abstract 1614: Murine matrigel plug assay for quick evaluation of anti-angiogenesis drugs.
Authors: Yanmei Sun, Xiaoming Song, Nan Li, Jie Cai, Qian Shi, Taiping Chen
Journal: Cancer Research (2013)

Abstract Angiogenesis plays important roles in disease processes such as tumor development and progression, as well as many physiological conditions. A few cancer drugs were successfully approved based on anti-angiogenesis mechanisms. More candidates are in different evaluation stages, including clinical phase II stages. Among many assays used for angiogenesis evaluation, Murine Matrigel Plug Assay (MMPA) is a relatively simple, highly effective in vivo assay to evaluate anti-angiogenesis responses of the test articles. Because of its simplicity and short assay duration, the assay is scalable for efficient screening of large number of test articles. However, the analysis of the plugs, usually with H&amp;E staining and microvessel counting, is time consuming and error prone, hampers the usage of this method as a general screening assay for test articles. Here, we set out to test a number of combinations of assay conditions, including mouse strains, angiogenesis inducers, varying days of treatment, and different routes of SOC drug treatments. More importantly, we tested plug analysis methods including H&amp;E staining, CD31 IHC staining, as well as hemoglobin concentration analysis. We demonstrated that hemoglobin concentration analysis results are corroborated by IHC staining as well as H&amp;E staining, in most of the conditions tested. Hemoglobin assay is less time consuming and easier to scale up. Thus MMPA followed by hemoglobin analysis may be suitable for large scale screening studies for angiogenesis modulators. Interestingly, CTX, one of the popular anti-cancer therapeutics, was shown in MMPA as a good anti-angiogenesis agent. In conclusion, the MMPA described may greatly facilitate the preclinical development of cancer therapeutics that target the angiogenesis. Citation Format: Yanmei Sun, Xiaoming Song, Nan Li, Jie Cai, Qian Shi, Taiping Chen. Murine matrigel plug assay for quick evaluation of anti-angiogenesis drugs. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1614. doi:10.1158/1538-7445.AM2013-1614
Italians Mount Strong Cancer Research Program
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Italians Mount Strong Cancer Research Program Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 19, 2 October 1991, Pages 1372–1374, https://doi.org/10.1093/jnci/83.19.1372 Published: 02 October 1991
PTH-191 <i>In vitro</i>modelling of reflux in the presence of the post-prandial acid pocket: validation of reflux supression by gaviscon products
Authors: J Fisher, V Strugala, PW Dettmar
Journal: Gut (2015)

<h3>Introduction</h3> The region of unbuffered acidity on top of the gastric contents after a meal, known as the post-prandial acid pocket,<sup>1</sup>is a chief aetiological factor responsible for the frequently experienced post-prandial reflux. We previously developed an <i>in vitro</i>model of the post-prandial acid pocket adhering to the physiological characteristics described in the clinical literature.<sup>2</sup>Here we further improve this <i>in vitro</i>model to simulate the occurrence of reflux events and also evaluate some anti-reflux products. <h3>Method</h3> A standard refluxogenic meal (McDonalds double sausage and egg McMuffin + black coffee) was blended with 40 ml 0.01 M HCl and transferred to the model stomach within a sealed water chamber. An acid pocket layer of 0.1 M HCl was applied to meet the established clinically measured parameters (70 ml and 2.5 cm depth). A reflux event was simulated by applying air pressure into the water chamber rapidly and the refluxate was captured in a syringe through the modelled lower oesophageal sphincter. The model was validated with two alginate-based anti-reflux products [UK manufactured Gaviscon Double Action (GDA) and USA manufactured Gaviscon Extra Strength (GES)]. <h3>Results</h3> Application of 50 ml of air to the <i>in vitro</i>post-prandial acid pocket model resulted in refluxate volume of 10 ml (SD 1.7 ml) which is a representative refluxate volume.<sup>3</sup> GDA suppressed reflux in the model in a dose dependent manner with 20 ml maximum GDA dose completely supressing 5 sequential reflux events. 10 ml GDA dose let through 2.7 ml of the reflux (mean of 5 events) and 2.5ml GDA dose let through 5.9 ml of the reflux (mean of 5 events). 20 ml maximum dose of GES did not supress reflux and 7.0 ml of the reflux was let through at maximum dose (mean of 5 events). <h3>Conclusion</h3> This <i>in vitro</i>model is representative of a fed stomach via introduction of a classic refluxogenic meal. The post-prandial acid pocket that is modelled represents that described in clinical studies and the model takes into account the pressure changes during a reflux event. Alginate raft forming anti-reflux products GDA and GES were chosen to validate the model and GDA was able to suppress reflux events in a dose dependent manner with maximum dose (20 ml) totally supressing all reflux events. In contrast GES that does not form a coherent buoyant raft<sup>4</sup>was a poor reflux suppressant. This <i>in vitro</i>model of reflux of the post-prandial acid pocket has potential to screen and evaluate test products without the need of clinical studies. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Fletcher, <i>et al</i>. Gastroenterology 2001;121:775–783 Fisher, <i>et al</i>. <i>UEG Journal</i>2014;<b>2</b>(Suppl 1):A578 Sifrim Gut 2005;<b>54</b>:175–178 Hampson, <i>et al</i>. Int J Pharm. 2005;294:137–147
Crystallography Getting Attention on Earth and in Space
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Crystallography Getting Attention on Earth and in Space Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 16, 19 August 1992, Pages 1228–1230, https://doi.org/10.1093/jnci/84.16.1228 Published: 19 August 1992
Efficacy of Oral Immunotherapy in Patients with Multiple Food Allergies
Authors: Shruti P. Wilson, Tina L.R. Dominguez, Alicia Sciancalepore, Daniela Pineda, Anjuli Mehrotra, Steven W. Rubinstein, Alan B. Goldsobel, Michael J. Mulligan, Robert C. Bocian, Nancy Cummings, Kari Nadeau
Journal: Journal of Allergy and Clinical Immunology (2013)
Cooperation and emergence: The missing elements of the Darwin machine
Authors: Jason Grotuss
Journal: Behavioral and Brain Sciences (2014)

Abstract The authors present a compelling argument for a science of intentional change by unifying evolutionary psychology (EP) with the standard social science model; however, since its inception, traditional EP models have not held up well to empirical scrutiny. The authors address the importance of cooperation in individuals and social systems, but the Darwin machine they propose does not adequately stress fundamental aspects of evolutionary processes.
EUS-guided hepaticogastrostomy for hepatic hilar obstruction
Authors: Takeshi Ogura, Daisuke Masuda, Akira Imoto, Eiji Umegaki, Kazuhide Higuchi
Journal: Endoscopy (2014)

EUS-guided hepaticogastrostomy (EUS-HGS) was recently developed to treat biliary decompression in patients with biliary obstruction, as an alternative to (failed) endoscopic biliary drainage or percutaneous transhepatic biliary drainage (PTBD), or when the papilla is inaccessible [1]. In addition, EUS-HGS has the advantage of internal drainage compared with PTBD. However, because EUS-HGS is a method of left intrahepatic biliary drainage, it is not usually indicated in patients with hepatic hilar obstruction [2]. We describe a case of successfully biliary drainage for hepatic hilar obstruction using a novel uncovered metallic stent with a fine-gauge delivery system.
Abstract P3-02-14: INTEGRATED PROGRAM FOR BREAST CANCER CONTROL: PARTIAL PRESENTATION OF THE RESULTS OBTAINED INTHE FIRST 24MONTHS OF OPERATION
Authors: EC Blanco, MM Borges, M Pinotti, MB Gennari, IM Ribeiro, CCP Nascimento, LFG Santos, RC Sahium
Journal: Cancer Research (2012)

Abstract Introduction Breast cancer is a public health problem in Brazil. This is due to the difficulty of primary prevention (eliminating risk factors or to diagnose and treat precursor lesions), with a consequent increase in the incidence and mortality from this cancer. The current challenge arises from the lack of access to a few specialized centers, which in turn ar e not always qualified for diagnosis and prompt treatment. Objective To develop a strategic plan aimed at two management priorities: resolubility diagnostic and fast treatment of women with clinical or secondary changes to mammographic screening. Methodology The Oswaldo Cruz Alemão Hospital (OCAH) in partnership with the Ministry of Health of Brazil has developed and deployed in the region of the Mooca - City of St. Paul the Integrated Program for Breast Cancer Control (IPBCC), which begins in the primary prevention (health education and removal of factors risk), continues with the mammographic detection and early diagnosis, modern instrumental in a Center for Diagnostic Detection and Tracking (CDDT), and culminates in the surgical and radiotherapy, ad juvant chemotherapy and hormone therapy or not, according to a standardized protocol. The care is coordinated in single query by mastologists trained in resolving service, with the participation of radiologists, oncologists, social workers, psychologists, nutritionists and health educators. Results From January 2010 to December 2011 were met 12266 women, mean age 58 years (range, 22–89) of which 100 were diagnosed with breast cancer and the proportion of carcinomas was of 8 per 1000. The detection rate mammography, ultrasound, and by both methods were: 0.30, 0.30 and 0.25, respectively. Forty-one percent of cancers corresponded to stages Tis N0M0 (3%) and T1N0M0 (38%) predominantly in women aged less than 50 years (38% of the sample). The average time between diagnosis and recorded start of surger y or chemotherapy was 42 days (range 19–68). As for quality of care, satisfaction was 99% (n = 12143). Conclusions The experience in resolving service provided a significant increase in the number of initial cases showing detection ratesper image consistent with the age distribution of population. It is expected that the tracking time and quality of service, allow the prevalent cancers cease to be diagnosed, privileging the incidents. The median time to diagnosis and early treatment of patients with cancer was significantly lower the average of 120 days recorded in some public reference services. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-02-14.
COMPARISON OF PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION WITH AND WITHOUT BALLOON AORTIC PREDILATATION. IN-HOSPITAL AND LONG-TERM MORTALITY
Authors: Konstantinos Stathogiannis, Konstantinos Toutouzas, George Latsios, Andreas Synetos, George Trantalis, Antonios Mastrokostopoulos, Seyrani Yuecel, Ulrich Gerckens, Eberhard Grube, Dimitrios Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Abstract P1-01-13: Patterns of definitive axillary management in the era prior to reporting ACOSOG Z0011: comparison between NCCN Centers and hospitals in Michigan
Authors: T Breslin, S Hwang, R Mamet, M Hughes, R Otteson, S Edge, B Moy, H Rugo, Y-N Wong, J Wilson, C Laronga, J Weeks, S Silver, P Marcom
Journal: Cancer Research (2012)

Abstract Background: The results of the ACOSOG- Z0011 trial have had potential practice changing implications for the management of patients with positive sentinel lymph node (SLN) undergoing lumpectomy and radiation for breast cancer. However, some evidence suggests a shift in axillary management even prior to the initial report of data supporting sentinel lymph node biopsy (SLNB) alone in mid-2010. We analyzed data in the National Comprehensive Cancer Network (NCCN) outcomes database from NCCN centers and the Michigan Breast Oncology Quality Initiative (MiBOQI) hospitals to examine institutional practice patterns with respect to use of completion axillary dissection (CALND) for SLN positive breast cancer in the years leading up to publication of these trial results. We hypothesized that CALND would be omitted more frequently in women treated at NCCN centers compared to those treated at MiBOQI programs. Methods: We identified 2,172 women with clinical T1/T2 N0 breast cancer who underwent breast surgery and SLNB and had a positive SLN from 2007 through 2010 at one of 12 participating NCCN centers or 12 MiBOQI sites. Patient and tumor characteristics, definitive breast procedure, year of diagnosis, and institutional affiliation were analyzed as predictors of use of SLNB alone in univariate Chi-Square and multivariable logistic regression models. Results: CALND was omitted in 314 (14.5%) of the 2,172 patients. Over time, there was a dramatic increase in the use of SLNB alone (12% in 2007 to 23% in 2010). In the univariate analyses, increased patient age, later year of diagnosis, lower T stage, and lower pathologic N stage were significant predictors of use of SLNB alone (all p &amp;lt; .0001). There was no association between definitive breast surgery type, hormone receptor status, Her-2 Neu status, or institutional affiliation and use of SLNB alone. In the multivariable model, older age at diagnosis, later year of diagnosis, and lower pathologic N stage remained significant independent predictors of SLNB alone. There were no significant differences in rates of omission of CALND between NCCN and MIBOQI sites. Conclusions: Omission of CALND occurred frequently in women with SLN positive breast cancer cared for in both NCCN and MiBOQI institutions in advance of reporting results of ACOSOG-Z0011. This shift was seen in management of patients undergoing lumpectomy as well as mastectomy. Further study is warranted to determine the extent of durable practice changes as well as any impact on survival and local-regional control. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-13.
A Gastric “Bee-Zoar”
Authors: John P. Lynch, Robin D. Rothstein
Journal: New England Journal of Medicine (1997)

To the Editor: Blum et al. (Jan. 2 issue) 1 reported the results of endovascular grafting for infrarenal aneurysms but did not address one emerging concern regarding the stability of the attachment site in the aorta.After successful exclusion from the circulation, aneurysms in the patients in their study had decreased in size by 2 to 4 mm at 12 months and by 5 to 15 mm at 24 months.3][4] These reports have demonstrated a reduction in the size of the aneurysm with successful endovascular exclusion (and enlargement associated with perigraft flow), but have also shown enlargement of the distal aortic neck in as little as six months.May et al. 3 suggest that this dilatation is not progressive; however, longterm results are unavailable.It is known that aortic size increases with age. 5 Continued enlargement of the aortic neck could lead to the unsealing of an endovascular reconstruction and reperfusion of the aneurysm sac with enlargement of the aneurysm.Late development of such perigraft flow has been reported in older patients.
Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma
Authors: M Mitterbauer, P Neumeister, P Kalhs, S Brugger, G Fischer, K Dieckmann, P Hoecker, W Hinterberger, W Linkesch, I Simonitsch, U Jaeger, K Lechner, C Mannhalter, G Mitterbauer, HT Greinix
Journal: Leukemia (2001)
Coassociation of ERα and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
Authors: AM Redmond, FT Bane, AT Stafford, M McIlroy, MF Dillon, AD Hill, LS Young
Journal: Cancer Research (2009)

Abstract Abstract #3032 The p160 coactivators AIB1 and SRC-1 are known to play a critical role in modulating transcription in breast cancer cells in conjunction with ligand-bound estrogen receptor. The interactions of the p160 proteins with this nuclear receptor are also important in the development of resistance to endocrine treatments. Using quantitative coassociation immunofluorescent microscopy, the colocalisation of the p160s and ERα was increased in the LY2 endocrine resistant cell line following treatment with the anti-estrogen tamoxifen in comparison to the endocrine sensitive MCF-7 cell line. In cell cultures derived from patient tumours at the time of primary surgery prior to treatment, there was an increase in association of the coactivators with ERα following treatment with estrogen but dissociation was evident in the presence of tamoxifen. Immunohistochemical staining of a tissue microarray, constructed from 560 breast cancer patients, revealed that SRC-1 was a strong predictor of reduced disease-free survival, both in patients receiving adjuvant tamoxifen treatment and untreated patients (p&amp;lt;0.0001 and p=0.0111 respectively). AIB1 was not a significant independent predictor of disease recurrence. SRC-1 was assigned a hazard ratio of 2.12 when survival analysis using a Cox proportional hazards model was applied. Quantitative coassociation analysis of the p160 coactivators with ERα in the patient TMA revealed significantly stronger colocalisation of SRC-1 and ERα in patients who are known to have relapsed than those patients who did not recur (p=0.00001). This data suggests SRC-1 is pivotal in tumour aggressiveness and is a powerful predictor of progression of disease in breast cancer patients. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3032.
Abstract LB-95: Construction and application of elastin-like polypeptide containing IL-4 receptor targeting peptide.
Authors: Sarangthem Vijaya Devi, Rang-Woon Park
Journal: Cancer Research (2013)

Abstract Cancer cells express a number of cell surface and matrix proteins that mediate tumor growth, migration, invasion, and metastasis. Screening for ligands that specifically target these molecules represents an excellent cancer therapy strategy. AP1 is a recently discovered peptide, homing onto atherosclerotic plaques and breast tumor tissues through selective binding to the interleukin 4 receptor (IL-4R). IL-4Rs are highly expressed in a variety of human tumors and it has been reported that IL-4/IL-4R interactions amplify the expression of some anti-apoptotic proteins thereby preventing drug-induced cancer cell death. Thus, targeting the IL-4R could possibly increase the therapeutic efficacy of anticancer drugs. Even though AP1 peptide possesses high target specificity and efficient tumor-homing, it has limitation due to easy elimination from the circulation and short half-life. To improve the binding affinity of AP1 and its avidity towards the IL-4R as well as its half-life, we incorporated multiple AP1 peptides into the elastin-like polypeptides (ELPs). Tandem repeats of ELP polymers containing AP1 peptide (AP1-ELPs) were prepared by using recursive directional ligation (RDL) method. The fluorescence-labeled A6V72, an AP1-ELP containing six AP1 units displayed superior binding ability to the IL-4R expressing cancer cell lines, H226 and MDA-MB-231. Surface plasmon resonance analysis showed that multivalent presentation of the targeting ligand AP1 in the ELP polymer backbone increased binding affinity to IL-4R approximately ~10, 000-fold compared to the free AP1 peptide, which is important for tumor targeting approach. The binding of AP1-ELPs was remarkably reduced when IL-4Rs were blocked with antibody against IL-4 receptor. Confocal microscopic imaging revealed the increased accumulation and uptake of A6V72 than V84 control ELP by H226 cells. Furthermore, the Cy5.5-labeled AP1-ELP showed excellent homing and longer retention in xenografted tumor tissues in mouse model. Immunohistological analysis of excised tumor tissues further verified the targeting of AP1-ELP to tumor. The present results imply that the AP1-ELPs can serve as novel carriers for effective delivery of therapeutic drugs to tumors. Citation Format: Sarangthem Vijaya Devi, Rang-Woon Park. Construction and application of elastin-like polypeptide containing IL-4 receptor targeting peptide. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-95. doi:10.1158/1538-7445.AM2013-LB-95
SP0138 The Long Term Outcome of Juvenile Idiopathic Arthritis
Authors: A. Ravelli
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Over the past four decades, a number of studies have evaluated the long-term outcome of juvenile idiopathic arthritis (JIA) and some of them have also attempted to identify early prognostic factors. Altogether, the available data indicate that JIA is not a benign disease because a considerable number of patients still enter adulthood with persistently active disease and a significant proportion of them may develop severe physical disability. Among the different disease categories, the long-term outcome is best in persistent oligoarthritis and worst in RF-positive polyarthritis; the outcome of systemic arthritis is widely variable, perhaps reflecting the heterogeneity of this JIA subtype. The comparison of earlier studies with those published in the last decade shows a decline in the frequency of patients with severe physical disability over the years; however, the proportion of patients who enter adulthood with active disease does not seem to be diminished. A recent study of 310 children with long-standing JIA (disease duration &gt; 5 years) seen between September 2002 and December 2006 showed that at follow-up evaluation only 21.8% met the criteria for inactive disease, and less than 50% met the definition of minimal disease activity. 19.2% had moderate to severe physical disability and 3.6% were in Steinbrocker class III–IV. Approximately 10% had major impairment in health-related quality of life (HRQL). A total of 34.2% had damage in &gt;1 joint or joint group and 26.1% showed extraarticular damage. Of the 125 patients who underwent a wrist radiograph, 35.2% had significant structural damage. 8.7% of patients had growth retardation. Altogether, these data suggest that patients currently followed in Western pediatric rheumatology centers have, on average, a low level of disease activity, little or no physical disability, and a satisfactory HRQOL. However, a sizable proportion of patients have persistently active disease, impaired function, and damage. Although there is considerable data on prognostic factors in JIA, prediction of long-term outcome early after disease presentation is still difficult because comparisons among studies are hindered for a variety of reasons. Thus, while a considerable body of data is accumulating, the definition of the longterm outcome of JIA remains imperfect. To increase the comparability of future analyses and to obtain generalizable information on the prognosis of JIA and its prediction, a great deal of effort should be directed toward standardizing the study design and the measurement of predictors and outcomes. Furthermore, the impact of recent therapeutic advances should be taken into account. <h3>Disclosure of Interest</h3> None Declared